Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene Sereno

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal for Immunotherapy of Cancer|March 9, 2022
Generalizable design parameters for soluble T cell receptor-based T cell engagersKaren J Froning, Arlene Sereno, Flora Huang, et al.
Journal for Immunotherapy of Cancer|July 13, 2021
Dichotomous impact of affinity on the function of T cell engaging bispecific antibodiesMathilde Poussin, Arlene Sereno, Xiufeng Wu, et al.
Molecular Cancer Therapeutics|August 19, 2010
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor responseJianying Dong, Stephen J Demarest, Arlene Sereno, et al.
Nature Communications|May 13, 2020
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecificsKaren Froning, Jack Maguire, Arlene Sereno, et al.
Nature Biotechnology|January 28, 2014
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interfaceSteven M Lewis, Xiufeng Wu, Anna Pustilnik, et al.
The Journal of Biological Chemistry|December 3, 2010
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityJianying Dong, Arlene Sereno, William B Snyder, et al.
The Journal of Biological Chemistry|February 13, 2009
Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivoAdam Doern, Xianjun Cao, Arlene Sereno, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal for Immunotherapy of Cancer|March 9, 2022
Generalizable design parameters for soluble T cell receptor-based T cell engagersKaren J Froning, Arlene Sereno, Flora Huang, et al.
Journal for Immunotherapy of Cancer|July 13, 2021
Dichotomous impact of affinity on the function of T cell engaging bispecific antibodiesMathilde Poussin, Arlene Sereno, Xiufeng Wu, et al.
Molecular Cancer Therapeutics|August 19, 2010
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor responseJianying Dong, Stephen J Demarest, Arlene Sereno, et al.
Nature Communications|May 13, 2020
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecificsKaren Froning, Jack Maguire, Arlene Sereno, et al.
Nature Biotechnology|January 28, 2014
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interfaceSteven M Lewis, Xiufeng Wu, Anna Pustilnik, et al.
The Journal of Biological Chemistry|December 3, 2010
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityJianying Dong, Arlene Sereno, William B Snyder, et al.
The Journal of Biological Chemistry|February 13, 2009
Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivoAdam Doern, Xianjun Cao, Arlene Sereno, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 1